Overcoming the barriers to effective glycaemic control for type 2 diabetes

Abstract

Get full access to this article

View all access options for this article.

References

European Diabetes Policy Group. A desktop guide to type 2 diabetes mellitus. Diabet Med 1999;16:716-30.

American Diabetes Association : clinical practice recommendations. Diabetes Care 1999;22(suppl 1):S1-114.

American Association of Clinical Endocrinologists. Medical guidelines for the management of diabetes mellitus: The AACE system of intensive diabetes self-management - 2002 Update. Endocrine Practice 2002;8(suppl 1):40-82.

New JP , Hollis S. , Campbell F. et al. Measuring clinical performance and outcomes from diabetes information systems: an observational study. Diabetologia 2000;43:836-43.

Liebl A. , Neiss A. , Spannheimer A. , Reitberger U. , Wagner T. , Gortz A. Costs of type 2 diabetes in Germany. Results of the CODE-2 study. Dtsch Med Wochenschr 2001;126:585-9.

Harris MI , Eastman RC , Cowie CC , Flegal KM , Eberhardt MS Racial and ethnic differences in glycemic control of adults with type 2 diabetes . Diabetes Care 1999;22:403-08.

Banerji MA , Buckley MC , Chaiken RL , Gordon D. , Lebovitz HE , Kral JG Liver fat, serum triglycerides and visceral adipose tissue in insulin-sensitive and insulin-resistant black men with NIDDM. Int J Obes Relat Metab Disord 1995;19:846-50.

Banerji MA , Faridi N. , Atluri R. , Chaiken RL , Lebovitz HE Body composition, visceral fat, leptin, and insulin resistance in Asian Indian men. J Clin Endocrinol Metab 1999;84:137-44.

Mokdad AS , Ford EH , Bowman BA et al. Diabetes trends in the US: 1990-1998. Diabetes Care 2000;23:1278-83.

10.

Day C. The rising tide of type 2 diabetes. Br J Diabetes Vasc Dis 2001;1:37-43.

11.

Panzram G. Mortality and survival in type 2 (non-insulin-dependent) diabetes mellitus . Diabetologia 1987;30:123-31.

12.

Gray A. , Raikou M. , McGuire A. et al. Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: economic analysis alongside randomised controlled trial (UKPDS 41). BMJ 2000; 320:1373-8.

13.

Caro JJ , Ward AJ , O'Brien JA Lifetime costs of complications resulting from type 2 diabetes in the US. Diabetes Care 2002;25:476-81.

14.

Jönsson B. The economic impact of diabetes. Diabetes Care 1998;21 (suppl 3):C7-10.

15.

UK Prospective Diabetes Study Group. Intensive blood glucose control with sulphonylurea or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.

16.

Stratton MI , Adler AI , Neil AW et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-12.

17.

UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-65.

18.

DeFronzo RA , Bonnadonna RC , Ferrannini E. Pathogenesis of NIDDM. A balanced overview. Diabetes Care 1992;15:318-68.

19.

DeFronzo RA Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidaemia and atherosclerosis. Neth J Med 1997;50:191-7.

20.

UK Prospective Diabetes Study Group. UK prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. UK Prospective Diabetes Study Group . Diabetes 1995;44:1249-58.

21.

Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403.

22.

Bailey CJ Diabetes control: Treating a moving target. Internal Med 1996; 17:90-101.

23.

Turner RC , Cull CA , Frighi V. , Holman RR Glycaemic control with diet, sulfonylurea, metformin or insulin in patients with type 2 diabetes mellitus: Progressive requirement for multiple therapies (UKPDS 49). JAMA 1999; 281:2005-12.

24.

Krentz AJ , Ferner RE , Bailey CJ Comparative tolerability profiles of oral antidiabetic agents. Drug Saf 1994;11:223-41.

25.

Howlett HC , Bailey CJ A risk-benefit assessment of metformin in type 2 diabetes mellitus . Drug Saf 1999;20:489-503.

26.

Haupt E. , Knick B. , Koschinsky T. et al. Oral antidiabetic combination therapy with sulphonylureas and metformin. Diabete Metab 1991;27:224-31.

27.

Hermann LS , Schersten B. , Melander A. Antihyperglycaemic efficacy, response prediction and dose-response relations of treatment with metformin and sulphonylurea, alone and in primary combination . Diabet Med 1994;11:953-60.

28.

Gribble FM , Manley SE , Levy JC Randomized dose ranging study of the reduction of fasting and postprandial glucose in type 2 diabetes by nateglinide (A-4166). Diabetes Care 2001;24:1221-25.

29.

Goldberg RB , Holvey SM , Schneider J. A dose-response study of glimepiride in patients with NIDDM who have previously received sulfonylurea agents. The Glimepiride Protocol #201 Study Group. Diabetes Care 1996 ;19:849-56.

30.

Garber AJ , Larsen J. , Schneider SH , Piper BA , Henry D. Simultaneous glyburide/metformin monotherapy is superior to component monotherapy as initial pharmacological treatment for type 2 diabetes. Diab Obes Metab 2002;4:201-08.

31.

Moses R. , Carter J. , Slobodniuk R. et al. Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 1999;22:119-24.

32.

DeFronzo RA , Goodman AM Efficacy of metformin in patients with non-insulin dependent diabetes mellitus. N Engl J Med 1995;333:541-9.

33.

Charpentier G. , Fleury F. , Kabir M. et al. Improved glycaemic control by addition of glimepiride to metformin monotherapy in type 2 diabetic patients. Diabet Med 2001;16:828-34.

34.

Marre M. , Howlett H. , Lehert P. , Allavoine T. Improved glycaemic control with metformin-glibenclamide combined tablet therapy (Glucovance®) in type 2 diabetic patients inadequately controlled on metformin . Diabet Med 2002;19:673-80.

35.

Blonde L. , Rosenstock J. , Mooradian AD , Piper BA , Henry D. Glyburide/ metformin combination product is safe and efficacious in patients with type 2 diabetes failing sulfonylurea therapy. Diabetes Obes Metab (in press).

36.

Veehof L. , Stewart R. , Haaijer-Ruskamp F. , Jong BM The development of polypharmacy. A longitudinal study. Fam Pract 2000;17:261-7.

37.

Paes AHP , Bakker A. , Soe-Agnie S-J. Impact of dosage frequency on patient compliance . Diabetes Care 1997;20:1512-17.

38.

Brown JB , Nichols GA , Glauber HS , Bakst A. Ten-year follow-up of antidiabetic drug use, nonadherence, and mortality in a defined population with type 2 diabetes mellitus. Clin Ther 1999;21:1045-57.

39.

Morris AD , Brennan GM , Macdonald TM , Donnan PT. Population-Based Adherence to Prescribed Medication in Type 2 Diabetes: A Cause for Concern. Diabetes 2000;49(suppl 1):A76.

40.

Donnan PT , MacDonald TM , Morris AD Adherence to prescribed oral hypoglycaemic medication in a population of patients with type 2 diabetes: a retrospective cohort study. Diabet Med 2002;19:279-84.

41.

UK Prospective Diabetes Study (UKPDS) Group. Quality of life in type 2 diabetic patients is affected by complications but not by policies to improve blood glucose or blood pressure control. Diabetes Care 1999; 22:1125-36.

42.

Guidelines Subcommittee. 1999 World Health Organisation - International Society of Hypertension. Guidelines for the Management of Hypertension. J Hypertens 1999;17:151-83.

43.

Joint National Committee. Sixth National Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC VI). Arch Intern Med 1997 ;157:2413-46.

44.

Winocour PH Effective diabetes care: a need for realistic targets. BMJ 2002;324:1577-80.